IPO
NOXXON Pharma N.V. announced today that the previously disclosed convertible bonds (see press releases of June 15 and August 1, 2018) have been listed on the Euronext Access market in Paris as notes convertible into NOXXON shares
Galapagos NV announced today the closing of its underwritten public offering of 2,961,373 American Depositary Shares (“ADSs”) at a price of $116.50 per ADS
Galapagos NV announces a share capital increase as a result of a public offering of American Depositary Shares.
Expedeon AG said today that the management is not aware of any change in the operational or strategic position of the Company which would justify the recent movement in the share price.
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
Galapagos NV announced today the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares (“ADSs”) at $116.50 per ADS, before underwriting discounts.
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
Galapagos NV announced today that it intends to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares (ADSs) in a U.S. public offering.
MorphoSys AG announced today that its shares will be included in the MDAX as of September 24, 2018 as announced by Deutsche Börse.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
PRESS RELEASES